Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Landos Biopharma, Inc. (LABP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0600-0.0200 (-1.85%)
At close: 04:00PM EDT
1.0400 -0.02 (-1.89%)
After hours: 05:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0800
Open1.0500
Bid1.0500 x 2200
Ask1.1300 x 800
Day's Range1.0000 - 1.0700
52 Week Range0.5500 - 16.1700
Volume126,862
Avg. Volume104,243
Market Cap44.443M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

    Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On Track to Complete Comprehensive Review of Clinical Development Plans Later this Year NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical c

  • GlobeNewswire

    Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial

    NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clini

  • GlobeNewswire

    Landos Names Gregory Oakes President and Chief Executive Officer

    Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This Year NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that Gregory Oakes has been named President and Chief Executive Officer, and has been

Advertisement
Advertisement